- Home
- AVIR vs ALLO Comparison
AVIR vs ALLO Comparison
Compare AVIR & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- ALLO
- Stock Information
- Founded
- AVIR 2012
- ALLO 2017
- Country
- AVIR United States
- ALLO United States
- Employees
- AVIR N/A
- ALLO N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVIR Health Care
- ALLO Health Care
- Exchange
- AVIR Nasdaq
- ALLO Nasdaq
- Market Cap
- AVIR 273.0M
- ALLO 277.8M
- IPO Year
- AVIR 2020
- ALLO 2018
- Fundamental
- Price
- AVIR $3.67
- ALLO $1.19
- Analyst Decision
- AVIR Hold
- ALLO Strong Buy
- Analyst Count
- AVIR 1
- ALLO 9
- Target Price
- AVIR $6.00
- ALLO $8.44
- AVG Volume (30 Days)
- AVIR 410.2K
- ALLO 2.6M
- Earning Date
- AVIR 08-06-2025
- ALLO 08-06-2025
- Dividend Yield
- AVIR N/A
- ALLO N/A
- EPS Growth
- AVIR N/A
- ALLO N/A
- EPS
- AVIR N/A
- ALLO N/A
- Revenue
- AVIR N/A
- ALLO N/A
- Revenue This Year
- AVIR N/A
- ALLO N/A
- Revenue Next Year
- AVIR N/A
- ALLO $199.63
- P/E Ratio
- AVIR N/A
- ALLO N/A
- Revenue Growth
- AVIR N/A
- ALLO N/A
- 52 Week Low
- AVIR $2.46
- ALLO $0.86
- 52 Week High
- AVIR $4.15
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- AVIR 76.11
- ALLO 42.23
- Support Level
- AVIR $3.15
- ALLO $1.18
- Resistance Level
- AVIR $3.35
- ALLO $1.29
- Average True Range (ATR)
- AVIR 0.13
- ALLO 0.10
- MACD
- AVIR 0.03
- ALLO -0.01
- Stochastic Oscillator
- AVIR 83.81
- ALLO 11.43
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.